Discovery and characterization of ORM‐11372, a novel inhibitor of the sodium‐calcium exchanger with positive inotropic activity
British Journal of Pharmacology2020Vol. 177(24), pp. 5534–5554
Citations Over TimeTop 14% of 2020 papers
Leena Otsomaa, Jouko Levijoki, Gerd Wohlfahrt, Hugh Chapman, Ari Koivisto, Karí Syrjänen, Tuula Koskelainen, Saara‐Elisa Peltokorpi, Piet Finckenberg, Aira Heikkilä, Najah Abi‐Gerges, Andre Ghetti, Paul E. Miller, Guy Page, Eero Mervaala, Norbert Nagy, Zsófia Kohajda, Norbert Jost, László Virág, András Varró, Julius Gy. Papp
Abstract
ORM-11372, a unique, novel, and potent inhibitor of human and rat NCX 1.1, is a positive inotropic compound. NCX inhibition can induce clinically relevant improvements in left ventricular contractions without affecting relaxation, heart rate, or BP, without pro-arrhythmic risk.
Related Papers
- → Levosimendan: From Basic Science to Clinical Trials(2011)26 cited
- → Hemodynamic effects of levosimendan in patients with low-output heart failure(2008)
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)
- → Οι επιδράσεις της χορήγησης του ευαισθητοποιητή ασβεστίου- Levosimendan- κατά την περιεγχειρητική περίοδο, σε υψηλού κινδύνου ασθενείς που υποβάλλονται σε μη καρδιοχειρουργικές επεμβάσεις(2009)